LSET Successfully Organised the LSET Exchange Series Exploring Innovation, Strategy and Emerging Tech
LSET organised the LSET Exchange Series, featuring weekly discussions on innovation, strategy and technology. Students actively contributed insights on topics like AI and cybersecurity. While industry experts were invited to participate, the first session featured student-led discussion. The series has concluded, with future sessions to be announced.
London, UK - 21 July, 2025 - The London School of Emerging Technology (LSET) successfully organised the LSET Exchange Series, a weekly programme of interactive sessions focused on key developments in innovation, business strategy and emerging technologies. The series brought together students, alumni and guest speakers for open discussions aimed at bridging academic learning with practical industry understanding.
The sessions were delivered online, with selected events held in a hybrid format to enable wider participation. Each session promoted active dialogue, live Q&A, and collaborative knowledge-sharing on current and emerging themes in the tech and business landscape.
Topics Covered
Each week focused on a different theme. Sessions explored:
Artificial Intelligence in Business and Technology
Cybersecurity and Risk Strategy
Solution Architecture and Systems Design
Digital Strategy and Transformation
Leadership and Innovation Culture
Meet the Panel
All sessions were moderated by Mayur Ramgir and featured contributions from LSET students specialising in Cybersecurity, Machine Learning, Automation Testing and Enterprise Development. While industry experts were invited to participate, they were not present during the initial session. Their involvement is anticipated in future sessions.
Participants
The first session welcomed:
LSET Students and Alumni - participating in discussions and gaining exposure to emerging trends
Guest Speakers - where applicable, contributing context to weekly themes
Industry Experts - invited to join future sessions for enhanced professional insights
Format and Engagement
LSET Exchange sessions were designed as collaborative forums, distinct from traditional lectures. Each included a Q&A segment and encouraged open contribution from attendees. Topics were announced via the student portal and mailing list in advance. Recordings were provided to enrolled students for review.
Outcomes
The LSET Exchange Series offered:
Opportunities to explore how emerging technologies are shaping modern industries
Insight into strategy, innovation and transformation
A platform for students to apply learning through discussion and peer engagement
Future session schedules and similar initiatives will be shared through LSET's official channels.
For collaboration or speaker enquiries, contact events@lset.uk
View session details and event archive: https://lset.uk/event/lset-exchange/
Video Link: https://www.youtube.com/embed/iSJRlW7IoF4
Media Contact
Company Name: London School of Emerging Technology
Contact Person: Jim Cohn
Email: Send Email
Phone: 02033699909
Address: 1 Cornhill
City: London
Country: United Kingdom
Website: www.lset.uk
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Market Online
16 minutes ago
- The Market Online
Contributors Corner Eps 13- The Corporate Crypto Strategy No One's Talking About, Until Now
Contributors Corner, Eps. 13 with Bundeep Singh Rangar Corporate balance sheets are going rogue. In a move that's shaking up traditional finance, companies like Strategy (formerly MicroStrategy), Nakamoto, and Metaplanet are ditching cash for Bitcoin — turning their treasuries into crypto war chests. It's bold, it's controversial, and it could redefine how corporations store and grow value. On this episode of Contributors Corner, we're back with our crypto and blockchain aficionado, Bandeep Singh Rangar, CEO of Fineqia to break down the wild west of crypto. We're dissecting the latest trend of public companies turning their balance sheets into Bitcoin vaults. Why are companies like Strategy (formerly MicroStrategy), Nakamoto, and Metaplanet hoarding Bitcoin? And if this is a speculative bet or a massive shift in how corporations protect value? Bandeep pulls back the curtain on how these 'Bitcoin treasury companies' are commanding insane premiums — sometimes trading at 4–5x the value of their holdings and why institutional investors are piling in. We also explore the rise of ETFs and how they provide a regulated backdoor to crypto exposure without the self-custody headaches. But here's the big question: Can these companies survive a long crypto winter? Bandeep breaks down the three critical factors — size, management, and asset mix — that will separate the survivors from the collapses. And if you've been wondering whether corporate giants like Apple or Amazon could jump into this game, Bandeep has thoughts on that too. This conversation cuts through the hype to reveal what's really driving the corporate shift toward crypto — and what it means for the future of traditional finance. Heard something you want unpacked even more? Or maybe you're already eyeballing a tokenized beach condo? Hit us in the comments or DM. 🎧 Listen now to this episode of Contributors Corner —next episode drops soon, stay tuned. DISCLAIMER: These conversations are packed full of useful knowledge for your portfolio decisions, and remember these are the opinions of our own, with vested interests in particular assets and companies. Always be sure you speak with your Financial Advisor and know your own risk tolerance . To stay up-to-date on all of your market news head to Join the discussion: Find out what everybody's saying check out the rest of Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here
Globe and Mail
2 hours ago
- Globe and Mail
J.P. Morgan Remains a Hold on WEX (WEX)
J.P. Morgan analyst Tien Tsin Huang maintained a Hold rating on WEX today and set a price target of $195.00. The company's shares opened today at $173.67. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Tsin Huang covers the Technology sector, focusing on stocks such as Cognizant, Accenture, and Block. According to TipRanks, Tsin Huang has an average return of 6.6% and a 58.85% success rate on recommended stocks. In addition to J.P. Morgan, WEX also received a Hold from Morgan Stanley's James Faucette in a report issued today. However, on the same day, TR | OpenAI – 4o reiterated a Buy rating on WEX (NYSE: WEX). The company has a one-year high of $217.47 and a one-year low of $110.45. Currently, WEX has an average volume of 519.1K. Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is neutral on the stock. Last month, Jennifer Kimball, the CAO of WEX sold 1,400.00 shares for a total of $183,512.00.
Globe and Mail
3 hours ago
- Globe and Mail
Bayer AG's Exploratory Study on Sepsis and DIC: A Potential Game-Changer?
Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bayer AG is conducting an exploratory study titled 'Exploratory Study to Investigate the Association Between the Onset of Disseminated Intravascular Coagulation (DIC) and Disease Progression With Different Biomarker Candidates as Well as Standard Clinical and Demographic Parameters in Adult Patients With Sepsis.' The study aims to understand how sepsis progresses to DIC, a severe blood disorder, by identifying biomarkers in patients admitted to intensive care units across Europe. This research is significant due to the limited treatment options for DIC, especially in sepsis patients. The study involves no investigational treatments; instead, participants receive standard medical care for sepsis. The focus is on collecting blood samples and clinical data to identify biomarkers indicative of DIC development. Designed as an interventional study with a single-group model, this research does not involve masking and primarily seeks to gather observational data. The study's primary purpose is to explore the progression of sepsis to DIC. The study began on January 29, 2025, with primary completion expected within 56 days for each participant. The latest update was submitted on July 22, 2025, indicating ongoing recruitment and data collection. This study could impact Bayer's stock performance by potentially enhancing its reputation in the medical research field, especially if the findings lead to improved understanding and treatment of sepsis-related DIC. Investors may view this as a positive development, although the absence of new drug interventions limits immediate commercial implications. The study is ongoing, with further details available on the ClinicalTrials portal.
